SMMT insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (right to buy) · Derivative security · Indirect ownership · By Spouse · Reported balance after transaction: 500000 · On November 20, 2026, the Spouse of Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025. | 2026-11-20 | 2026-11-20 | 300,000 shares/units | SEC 4 | Follow |
| DUGGAN ROBERT W Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Indirect ownership · By Spouse · Reported balance after transaction: 831000 · On November 20, 2026, the Spouse of Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. | 2026-11-20 | 2026-11-20 | 300,000 shares/units | SEC 4 | Follow |
| Zanganeh Mahkam Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 500000 · On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025. | 2026-11-20 | 2026-11-20 | 300,000 shares/units | SEC 4 | Follow |
| Zanganeh Mahkam Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 831000 · On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. | 2026-11-20 | 2026-11-20 | 300,000 shares/units | SEC 4 | Follow |
| DUGGAN ROBERT W Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (right to buy) · Derivative security · Indirect ownership · By Spouse · Reported balance after transaction: 800000 · On November 16, 2026, the Spouse of Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025. | 2026-11-16 | 2026-11-16 | 500,000 shares/units | SEC 4 | Follow |
| DUGGAN ROBERT W Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Indirect ownership · By Spouse · Reported balance after transaction: 531000 · On November 16, 2026, the Spouse of Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. | 2026-11-16 | 2026-11-16 | 500,000 shares/units | SEC 4 | Follow |
| Zanganeh Mahkam Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 800000 · On November 16, 2026, the Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025. | 2026-11-16 | 2026-11-16 | 500,000 shares/units | SEC 4 | Follow |
| Zanganeh Mahkam Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 531000 · On November 16, 2026, the Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. | 2026-11-16 | 2026-11-16 | 500,000 shares/units | SEC 4 | Follow |
| Soni Manmeet Singh COO and CFO · Director · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 100000 · On November 16, 2026, the Reporting Person exercised an option to purchase 100,000 shares of the Issuer's common stock at an exercise price of $1.37 per share. · The option was granted on December 23, 2019. The shares underlying the option vested in four equal annual installments, with the first such installment beginning on December 23, 2020. | 2026-11-16 | 2026-11-16 | 100,000 shares/units | SEC 4 | Follow |
| Soni Manmeet Singh COO and CFO · Director · Summit Therapeutics Inc. | SMMT Summit Therapeutics Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 3224375 · On November 16, 2026, the Reporting Person exercised an option to purchase 100,000 shares of the Issuer's common stock at an exercise price of $1.37 per share. · Holdings include shares previously acquired through exempt transactions pursuant to the Issuer's employee stock purchase plan. | 2026-11-16 | 2026-11-16 | 100,000 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.